AstraZeneca and Handa Pay $5.475M to Settle Seroquel XR Antitrust Lawsuit Over Generic Medication Blockage
Deadline
Deadline: June 9, 2025
Total Settlement Amount
Total amount allocated for all claims
Individual Payout Range
Estimated amount per eligible claim
Proof of Purchase
Class members must provide documentation of their purchases, payments and/or reimbursements for 50 mg, 150 mg, 200 mg and 300 mg strengths of Seroquel XR and generic quetiapine fumarate ER.
Settlement Summary
Pharmaceutical giants AstraZeneca and Handa Pharmaceuticals were embroiled in a lawsuit alleging they violated antitrust laws by preventing the sale of generic versions of Seroquel XR, an antipsychotic medication used to treat conditions like schizophrenia, bipolar disorder, and depression. The companies have agreed to pay a combined $5.475 million to resolve these claims, which state that their actions caused third-party payers to overpay for the branded and generic medication. The settlement benefits entities that purchased, paid, and/or reimbursed the cost of Seroquel XR or its generic counterpart in specific states between September 5, 2015, and December 9, 2024.
Entities Involved
Eligibility Requirements
- Entities that purchased, paid, and/or reimbursed some or all of the purchase price of Seroquel XR or quetiapine fumarate ER 50 mg, 150 mg, 200 mg and/or 300 mg tablets between Sept. 5, 2015, and Dec. 9, 2024
- Must be located in the eligible states listed
Featured Investigations
Hair Relaxer Cancer Lawsuits
Study links frequent chemical hair straightener use to 50% higher uterine cancer risk in Black women. Legal action is underway against major relaxer brands. Learn about your rights and potential compensation.
Apple Siri Privacy Settlement - Up to $20 Per Device Compensation Available
Apple has agreed to pay $95 million to settle claims that Siri recorded conversations without consent and potentially shared data with advertisers. Eligible device owners can receive up to $20 per device. The settlement awaits final approval.
Stay Updated
Subscribe to our newsletter for the latest settlement updates and news.
Important Notice About Filing Claims
Submitting false information in a settlement claim is considered perjury and will result in your claim being rejected. Fraudulent claims harm legitimate class members and may result in legal consequences.
If you are unsure about your eligibility for this settlement, please visit the official settlement administrator’s website using the link provided above. Review the eligibility criteria carefully before submitting a claim.
Class Action Champion is an independent information resource and is not affiliated with any settlement administrator, law firm, or court. We provide settlement information as a service to help connect eligible class members with legitimate settlements.